²é¿´: 496  |  »Ø¸´: 8
µ±Ç°Ö÷ÌâÒѾ­´æµµ¡£
¡¾ÐüÉͽð±Ò¡¿»Ø´ð±¾ÌûÎÊÌ⣬×÷Õßgufansmile½«ÔùËÍÄú 6 ¸ö½ð±Ò
µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû

gufansmile

Í­³æ (СÓÐÃûÆø)

[ÇóÖú] lÂÛÎÄͶ¸åÇóÖú£¡¡¾ÓÐЧÆÚÖÁ2008Äê12ÔÂ1ÈÕ¡¿ÇóÖúÍê³É

ÇëÎʸ÷λÓÐûÓÐͶ¹ýjournal of enzyme inhibition and medicinal chemistryÕâ¸öÔÓÖ¾£¬Õâ¸öÔÓÖ¾µÄͶ¸å·½Ê½ÊÇÓʼĵ½Ö÷±àÓÊÏäÂð£¿Ò»°ãÉó¸åÈÕÆÚÊǶà¾ÃÄØ£¿Õâ¸ö±»½ÓÊյĹý³Ì´ó¸ÅÐèÒª¶à¾Ã°¡?

лл´ó¼ÒµÄ»Ø´ð£¬±ÏÒµÔÚ¼´£¬Íò·Ö׿±£¬Çë¸øÓèÖ¸µ¼£¬Ð»Ð»¸÷λÁ˰¡!

[ Last edited by gufansmile on 2008-10-22 at 12:15 ]

» ²ÂÄãϲ»¶

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

rangaisuifeng

Òø³æ (ÕýʽдÊÖ)

×£¸£´ó¼Ò¶¼ÄÜ˳Àû±ÏÒµ°¡
¼ÈÈ»Ç°ÃæµÄ·£¬ÎÒÃÇÎÞ·¨Ô¤Öª£¬¾ÍÈÃÎÒÃǴ󵨵ÄÈ¥³¢ÊÔ°É
7Â¥2008-10-20 09:30:15
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
²é¿´È«²¿ 9 ¸ö»Ø´ð

crazyff12345

½ð³æ (ÕýʽдÊÖ)

¡ï
sanko211(½ð±Ò+1,VIP+0):´úÂ¥Ö÷·¢½ð±Ò£¬¸ÐлӦÖú£¬»¶Ó­³£À´Óн±ÎÊ´ð°æ^_^
3. Submission of Manuscripts

Authors are encouraged to submit manuscripts electronically by email to Professor H. John Smith at jeimc@Cardiff.ac.uk. Electronic submissions should be sent as email attachments using a standard word processing program, such as MSWORD.

If email submission is not possible, please send to the above address an electronic version on disk along with three paper copies together with one set of high quality figures for reproduction. When the accepted paper is submitted in final form, please send two paper copies and a copy on disk.

Please make sure your contact address information is clearly visible on the outside of all packages you are sending to the Editor.

4. Preparation of Manuscripts

Journal of Enzyme Inhibition and Medicinal Chemistry considers all manuscripts on the strict condition that they have been submitted only to Journal of Enzyme Inhibition and Medicinal Chemistry, that they have not been published already, nor are they under consideration for publication or in press elsewhere. Authors who fail to adhere to this condition will be charged with all costs which Journal of Enzyme Inhibition and Medicinal Chemistry incurs and their papers will not be published.

Research article contributions to Journal of Enzyme Inhibition and Medicinal Chemistry must report original research and all manuscripts will be subjected to review by referees. The following guidelines apply:

For all manuscripts non-discriminatory language is mandatory. Sexist or racist terms should not be used.
Each paper should have three to six keywords.
Papers are accepted only in English.
Manuscripts for hard-copy submission should be typed on single sides of good quality white A4 or 8 x 11 inch paper, double-spaced throughout including the reference section, with wide (3 cm) margins.
All the authors of a paper should include their full names, affiliations, postal addresses, telephone and fax numbers and email addresses on the cover page of manuscripts.
Abstracts of 100 - 150 words are required for all papers submitted and should precede the text of a paper.
Manuscripts should be compiled in the following order: title page; abstract; keywords; main text; acknowledgments; appendixes (as appropriate); references; table(s) with caption(s) (on individual sheets); figure caption(s) (as a list).
Section headings should be concise and numbered sequentially, using a decimal system for subsections.
Authors must adhere to SI units.
For information on submitting animations, movie files and sound files or any additional information including indexes and calendars please click here.
When using a word which is or is asserted to be a proprietary term or trade mark authors must use the symbol ® or ™ or alternatively a footnote can be inserted using the wording below:

This article includes a word that is or is asserted to be a proprietary term or trade mark. Its inclusion does not imply it has acquired for legal purposes a non-proprietary or general significance, nor is any other judgement implied concerning its legal status.
5. Ethics and Consent

When reporting experiments on human subjects, authors should indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 1983. Do not use patients' names, initials, or hospital numbers, especially in illustrative material. Papers including animal experiments or clinical trials must be conducted with approval by the local animal care or human subject committees, respectively.

Identifying information should not be published in written descriptions, photographs, and pedigrees, unless the information is essential for scientific purposes and the patient (or parent or guardian) gives written informed consent for publication. Informed consent for this purpose requires that the patient be shown the manuscript to be published.

6. Declaration of Interest

It is the policy of all Informa Healthcare, to adhere in principle to the Conflict of Interest policy recommended by the International Committee of Medical Journal Editors (ICMJE). (http://www.icmje.org/index.html#conflict)

All authors must disclose any financial and personal relationships with other people or organisations that could inappropriately influence (bias) their work. It is the sole responsibility of authors to disclose any affiliation with any organisation with a financial interest, direct or indirect, in the subject matter or materials discussed in the manuscript (such as consultancies, employment, paid expert testimony, honoraria, speakers bureaus, retainers, stock options or ownership, patents or patent applications or travel grants) that may affect the conduct or reporting of the work submitted. All sources of funding for research are to be explicitly stated. If uncertain as to what might be considered a potential conflict of interest, authors should err on the side of full disclosure.

All submissions to the journal must include full disclosure of all relationships that could be viewed as presenting a potential conflict of interest. If there are no conflicts of interest, authors should state that there are none. This must be stated at the point of submission (within the manuscript after the main text under a subheading "Declaration of interest" and where available within the appropriate field on the journal's Manuscript Central site). This may be made available to reviewers and will appear in the published article at the discretion of the Editors or Publisher.

If no conflict is declared, the following statement will be attached to all articles:

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

The intent of this policy is not to prevent authors with these relationships from publishing work, but rather to adopt transparency such that readers can make objective judgements on conclusions drawn.

7. Authorship Contributions

Contributions must be substantial in order to warrant authorship. Each author should have participated sufficiently in the work to take public responsibility for the content. All other contributors should be listed as acknowledgements.

8. Colour Charges

Any figure submitted as a colour original will appear in colour in the journal's online edition free of charge and can be downloaded. Paper copy colour reproduction will only be considered on condition that authors contribute to the associated costs. The charges are 500/US$900 for the first colour page and 250/US$450 for each colour page after per article.

There are no charges for non-colour pages.

9. Proofs

The Editor reserves the right to proceed to press without submitting page proofs to the author. However, usual practice will involve corresponding authors receiving e-mail notification with a password and Web address from which to download a PDF. Hard copies of proofs will not be mailed. To avoid delays in publication, corrections to proofs must be returned within 48 hours, by electronic transmittal, fax or mail. Authors will be charged for excessive correction at this stage of production.

If authors do not return page proofs promptly, the Editor reserves the choice to either delay publication to a subsequent issue or to proceed to press without author corrections.

10. Offprints and Reprints

Offprints and reprints of articles published in Journal of Enzyme Inhibition and Medicinal Chemistry can be purchased once the article has been published online. You will be given the opportunity to order offprints and/or reprints via Rightslink® at the time at which you receive proofs of your article. Copies of the Journal can be purchased at the authors' preferential rate of 15.00/$25.00 per copy.

11. Copyright

It is a condition of publication that authors assign copyright or license the publication rights in their articles, including abstracts, to Informa UK Ltd. This enables us to ensure full copyright protection and to disseminate the article, and the Journal, to the widest possible readership in print and electronic formats as appropriate. Authors may, of course, use the article elsewhere after publication without prior permission from Informa UK Ltd., provided that acknowledgement is given to the Journal as the original source of publication, and that Informa Healthcare is notified so that our records show that its use is properly authorised. Authors retain a number of other rights under the Informa UK Ltd. rights policies documents. These policies are referred to at the Copyright FAQs page.

Authors are themselves responsible for obtaining permission to reproduce copyright material from other sources. See Copyright Permission for full details.

A copyright agreement form can be downloaded by corresponding authors of accepted manuscripts with proofs. This should be signed and returned to Taylor & Francis
http://ff.a.5d6d.com/userdirs/f/d/shouxiao/attachments/forumid_27/20070928_b48e1cab0b88b5f5a7fdfvx51XwzGRr4.jpg
2Â¥2008-10-18 13:52:34
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

zys666

½ð³æ (ÕýʽдÊÖ)

»Ø¸´

¡ï ¡ï
sanko211(½ð±Ò+2,VIP+0):´úÂ¥Ö÷·¢½ð±Ò£¬¸ÐлӦÖú£¬»¶Ó­³£À´Óн±ÎÊ´ð°æ^_^
²»ÒªÓʼÄÄÇÌ«ÂýÁË £¬Äã´ò¿ª¸ÃÆÚ¿¯Í¨¹ýEESϵͳÔÚÏßÌá½»
3Â¥2008-10-18 13:58:14
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

hikylin

ÖÁ×ðľ³æ (ÖøÃûдÊÖ)

¡ï ¡ï ¡ï
sanko211(½ð±Ò+3,VIP+0):´úÂ¥Ö÷·¢½ð±Ò£¬¸ÐлӦÖú£¬»¶Ó­³£À´Óн±ÎÊ´ð°æ^_^
ÔÚÏßͶµÝ£¬http://www.informaworld.com/smpp/title~content=t713642123ÊÇÊ×Ò³£¬
¾ßÌåÎÒûÓÐͶ¹ý£¬Ò²Ìý±ðÈË˵¹ý£¬ËÙ¶ÈÒ»°ã°É£¬¶¼Êǰ´ÔÂÀ´ËãµÄ¡£°¥£¬ÎÒºÍÂ¥Ö÷Ò»ÑùµÄ¾³¿ö°¡
4Â¥2008-10-18 14:57:51
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
²»Ó¦Öú È·¶¨»ØÌûÓ¦Öú (×¢Ò⣺ӦÖú²Å¿ÉÄܱ»½±Àø£¬µ«²»ÔÊÐí¹àË®£¬±ØÐëÌîд15¸ö×Ö·ûÒÔÉÏ)
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] Çóµ÷¼Á +5 Mqqqqqq 2026-03-19 5/250 2026-03-20 20:46 by zhukairuo
[¿¼ÑÐ] Ò»Ö¾Ô¸»ªÖÐũҵ071010£¬×Ü·Ö320Çóµ÷¼Á +3 À§À§À§À§À¤À¤ 2026-03-20 3/150 2026-03-20 20:38 by ѧԱ8dgXkO
[¿¼ÑÐ] 260Çóµ÷¼Á +3 ÖìÜÆÁÕ 2026-03-20 3/150 2026-03-20 20:35 by ѧԱ8dgXkO
[¿¼ÑÐ] Ò»Ö¾Ô¸Î÷ÄϽ»Í¨ ר˶ ²ÄÁÏ355 ±¾¿ÆË«·Ç Çóµ÷¼Á +4 Î÷ÄϽ»Í¨×¨²Ä355 2026-03-19 4/200 2026-03-20 11:39 by »¨¿ª¸»¹óÐÒ¸£ÈËÉ
[¿¼ÑÐ] 081700»¯¹¤Ñ§Ë¶µ÷¼Á +3 ¡¾1¡¿ 2026-03-16 3/150 2026-03-19 23:40 by edmund7
[¿¼ÑÐ] 307Çóµ÷¼Á +9 ÀäóÏ123 2026-03-17 9/450 2026-03-19 22:44 by ѧԱ8dgXkO
[¿¼²©] É격26Äê +3 °Ë6°Ë68 2026-03-19 3/150 2026-03-19 19:43 by nxgogo
[¿¼ÑÐ] 085601²ÄÁϹ¤³Ìר˶Çóµ÷¼Á +10 Ľº®mio 2026-03-16 10/500 2026-03-19 15:26 by ¶¡¶¡*
[¿¼ÑÐ] Ò»Ö¾Ô¸Ìì½ò´óѧ»¯Ñ§¹¤ÒÕרҵ£¨081702£©315·ÖÇóµ÷¼Á +11 yangfz 2026-03-17 11/550 2026-03-19 15:06 by houyaoxu
[¿¼ÑÐ] Ò»Ö¾Ô¸ Î÷±±´óѧ £¬070300»¯Ñ§Ñ§Ë¶£¬×Ü·Ö287£¬Ë«·ÇÒ»±¾£¬Çóµ÷¼Á¡£ +3 ³¿»èÏßÓëÐǺ£ 2026-03-19 3/150 2026-03-19 13:36 by houyaoxu
[¿¼ÑÐ] Ò»Ö¾Ô¸ÎäÀí²ÄÁÏ305·ÖÇóµ÷¼Á +5 ÏëÉϰ¶µÄÀðÓã 2026-03-18 6/300 2026-03-18 17:53 by Î޼ʵIJÝÔ­
[¿¼ÑÐ] 0854£¬¼ÆËã»úÀàÕÐÊÕµ÷¼Á +3 ºúÀ±ÌÀ·ÅÌÇ 2026-03-15 6/300 2026-03-18 12:09 by Éϰ¶Éϰ¶¡­¡­..
[¿¼ÑÐ] ²ÄÁÏ£¬·ÄÖ¯£¬ÉúÎ0856¡¢0710£©£¬»¯Ñ§ÕÐÉúÀ² +3 Eember. 2026-03-17 9/450 2026-03-18 10:28 by Eember.
[¿¼ÑÐ] 0703»¯Ñ§336·ÖÇóµ÷¼Á +6 zbzihdhd 2026-03-15 7/350 2026-03-18 09:53 by zhukairuo
[¿¼ÑÐ] ÓÐûÓеÀÌú/ÍÁľµÄÏëµ÷¼ÁÄÏÁÖ£¬¸ø×Ô¼ºÕÐʦµÜÖС« +3 TqlXswl 2026-03-16 7/350 2026-03-17 15:23 by TqlXswl
[¿¼ÑÐ] ¿¼Ñе÷¼Á +3 ä¿ya_~ 2026-03-17 5/250 2026-03-17 09:25 by Winj1e
[¿¼ÑÐ] ¶«ÄÏ´óѧ364Çóµ÷¼Á +5 JasonYuiui 2026-03-15 5/250 2026-03-16 21:28 by ľ¹Ï¸à
[¿¼ÑÐ] Ò»Ö¾Ô¸211 0703·½Ïò310·ÖÇóµ÷¼Á +3 ŬÁ¦·Ü¶·112 2026-03-15 3/150 2026-03-16 16:44 by houyaoxu
[¿¼ÑÐ] 321Çóµ÷¼Á +5 ´óÃ×·¹£¡ 2026-03-15 5/250 2026-03-16 16:33 by houyaoxu
[¿¼ÑÐ] 080500£¬²ÄÁÏѧ˶302·ÖÇóµ÷¼ÁѧУ +4 ³õʶ¿ÉÀÖ 2026-03-14 5/250 2026-03-14 21:08 by peike
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û